fluvoxamine

Summary

Summary: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.

Top Publications

  1. Geldof M, Freijer J, Van Beijsterveldt L, Timmerman P, Ahnaou A, Drinkenburg W, et al. Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies. Eur J Pharm Sci. 2007;30:45-55 pubmed
    ..This analysis characterizes and evaluates the population PK of fluvoxamine in rat plasma using nonlinear mixed effects modeling...
  2. Higuchi H. [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods]. Nihon Shinkei Seishin Yakurigaku Zasshi. 2010;30:71-6 pubmed
    ..In a fluvoxamine study, sixty-six patients with major depressive disorder were treated with fluvoxamine, 100-200 mg/day, for 6 ..
  3. Kato M, Fukuda T, Wakeno M, Fukuda K, Okugawa G, Ikenaga Y, et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology. 2006;53:186-95 pubmed
    ..transporter (SERTPR), and investigated the different characteristics of clinical responses to paroxetine and fluvoxamine. A total of 100 Japanese patients affected by major recurrent depression were enrolled in a randomized 6-week ..
  4. Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology. 2006;31:825-31 pubmed
    ..CytochromeP450 (CYP) 2D6 may also be associated with the side effects induced by fluvoxamine, since the plasma fluvoxamine concentration depends on a CYP2D6 gene polymorphism...
  5. Rojas Corrales M, Berrocoso E, Gibert Rahola J, Mico J. Antidepressant-like effect of tramadol and its enantiomers in reserpinized mice: comparative study with desipramine, fluvoxamine, venlafaxine and opiates. J Psychopharmacol. 2004;18:404-11 pubmed
    ..Moreover, we compared the effects of tramadol and its enantiomers with those of antidepressants (desipramine, fluvoxamine and venlafaxine) and opiates [morphine (-)-methadone and levorphanol]...
  6. Tsunoka T, Kishi T, Ikeda M, Kitajima T, Yamanouchi Y, Kinoshita Y, et al. Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:875-9 pubmed publisher
    ..we studied the association between Group II mGluR genes (GRM2 and GRM3) and mood disorders and the efficacy of fluvoxamine treatment in Japanese MDD patients...
  7. Carrasco J, Sandner C. Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract. 2005;59:1428-34 pubmed
    ..For example, fluvoxamine has affinity for sigma(1)-receptors -- a property likely to be responsible for its particular efficacy in ..
  8. Hayashi T, Miyata M, Nagata T, Izawa Y, Kawakami Y. Intracerebroventricular fluvoxamine administration inhibited pain behavior but increased Fos expression in affective pain pathways. Pharmacol Biochem Behav. 2009;91:441-6 pubmed publisher
    Anti-nociceptive effects of fluvoxamine, administered by intracerebroventricular (i.c.v.) injection, include inhibited pain behavior in both formalin-induced acute pain (p<0.05-0.01) and sciatic nerve ligation-allodynia (p<0.03)...
  9. Darwish I, Abdine H, Amer S, Al Rayes L. Spectrophotometric study for the reaction between fluvoxamine and 1,2-naphthoquinone-4-sulphonate: Kinetic, mechanism and use for determination of fluvoxamine in its dosage forms. Spectrochim Acta A Mol Biomol Spectrosc. 2009;72:897-902 pubmed publisher
    ..study was carried out, for the first time, to investigate the reaction between the antidepressant fluvoxamine (FXM) and 1,2-naphthoquinone-4-sulphonate (NQS) reagent...

More Information

Publications70

  1. Nakatani E, Nakagawa A, Nakao T, Yoshizato C, Nabeyama M, Kudo A, et al. A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine. Psychother Psychosom. 2005;74:269-76 pubmed
    The aim of this study was to confirm and compare the efficacy of fluvoxamine (the only licensed SSRI for treatment for OCD in Japan) and behavior therapy in treating Japanese patients with OCD...
  2. Katsuyama S, Sato K, Yagi T, Kishikawa Y, Nakamura H. Effects of repeated milnacipran and fluvoxamine treatment on mechanical allodynia in a mouse paclitaxel-induced neuropathic pain model. Biomed Res. 2013;34:105-11 pubmed
    ..Milnacipran, a serotonin/noradrenaline reuptake inhibitor and fluvoxamine, a selective serotonin reuptake inhibitor, have shown efficacy against several chronic pain syndromes...
  3. Nakano M, Osada K, Misonoo A, Fujiwara K, Takahashi M, Ogawa Y, et al. Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473-phosphorylation of Akt-1 in PC12 cells. Life Sci. 2010;86:309-14 pubmed publisher
    ..Furthermore, the PLC-gamma/IP(3)/Ca(2+) pathway is regulated by the sigma-1 receptors. Here, we examined whether fluvoxamine (FLV) activated Akt-1 and increased phosphorylation of Akt-1 via sigma-1 receptor in PC12 cells.
  4. Kishi T, Kitajima T, Ikeda M, Yamanouchi Y, Kinoshita Y, Kawashima K, et al. Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population. Neuropsychobiology. 2009;59:234-8 pubmed publisher
    ..Therefore, we examined the association between the orphan nuclear receptor Rev-erbalpha gene (NR1D1) and the efficacy of fluvoxamine treatment in 118 Japanese patients with major depressive disorder.
  5. Dursun H, Bilici M, Albayrak F, Ozturk C, Saglam M, Alp H, et al. Antiulcer activity of fluvoxamine in rats and its effect on oxidant and antioxidant parameters in stomach tissue. BMC Gastroenterol. 2009;9:36 pubmed publisher
    ..date, however, there is no information available regarding the antiulcer activity for a similar antidepressant, fluvoxamine. This study aimed to investigate the antiulcer effects of fluvoxamine and to determine its relationship with ..
  6. Geldof M, Freijer J, Peletier L, Van Beijsterveldt L, Danhof M. Mechanistic model for the acute effect of fluvoxamine on 5-HT and 5-HIAA concentrations in rat frontal cortex. Eur J Pharm Sci. 2008;33:217-29 pubmed publisher
    ..7 and 7.3mg/kg fluvoxamine. Directly after administration of fluvoxamine, concentrations of 5-HT were increased to approximately 450-600% ..
  7. Dell Osso B, Allen A, Hollander E. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother. 2005;6:2727-40 pubmed
    b>Fluvoxamine is the selective serotonin re-uptake inhibitor with the largest database in the treatment of obsessive-compulsive disorder, a severe, and often chronic, anxiety disorder associated with substantial impairment in functioning...
  8. Saitoh A, Yamaguchi K, Tatsumi Y, Murasawa H, Nakatani A, Hirose N, et al. Effects of milnacipran and fluvoxamine on hyperemotional behaviors and the loss of tryptophan hydroxylase-positive cells in olfactory bulbectomized rats. Psychopharmacology (Berl). 2007;191:857-65 pubmed
    ..It has been reported that many of the behavioral and serotonergic neuronal changes observed in olfactory bulbectomy (OBX) were improved by subchronic administration of a variety of antidepressants...
  9. Kurita M, Sato T, Nishino S, Ohtomo K, Shirakawa H, Mashiko H, et al. Effects of fluvoxamine on behavioral and psychological symptoms of dementia in Alzheimer's disease: a report of three cases. Fukushima J Med Sci. 2006;52:143-8 pubmed
    To report 3 cases of severe behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD) with fluvoxamine treatment and to discuss the treatment implications for use of the drug.
  10. Miura H, Qiao H, Kitagami T, Ohta T, Ozaki N. Effects of fluvoxamine on levels of dopamine, serotonin, and their metabolites in the hippocampus elicited by isolation housing and novelty stress in adult rats. Int J Neurosci. 2005;115:367-78 pubmed
    The authors investigated the effects of fluvoxamine on neurochemical changes in the hippocampus elicited by isolation housing and novelty stress. Male F344 rats (11 w) were housed one per cage for four weeks...
  11. Nagata H, Nozaki M, Nakano H. Short-term combinational therapy of low-dose estrogen with selective serotonin re-uptake inhibitor (fluvoxamine) for oophorectomized women with hot flashes and depressive tendencies. J Obstet Gynaecol Res. 2005;31:107-14 pubmed
  12. Takano A, Suhara T, Ichimiya T, Yasuno F, Suzuki K. Time course of in vivo 5-HTT transporter occupancy by fluvoxamine. J Clin Psychopharmacol. 2006;26:188-91 pubmed
    ..In this study, we measured the time course of the selective serotonin reuptake inhibitor fluvoxamine in the human brain based on serotonin transporter (5-HTT) occupancy by positron emission tomography...
  13. Yasui Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol. 2004;44:1223-9 pubmed
    ..Lansoprazole is a substrate of CYP2C19 and CYP3A4. The aim of this study was to compare the inhibitory effects of fluvoxamine, an inhibitor of CYP2C19, on the metabolism of lansoprazole between CYP2C19 genotypes...
  14. Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology. 2007;32:514-21 pubmed
    This study was undertaken to examine the effects of the selective serotonin reuptake inhibitors fluvoxamine and paroxetine on cognitive deficits in mice after repeated administration of the N-methyl-D-aspartate receptor antagonist ..
  15. Marcinko D, Karlovic D. Oniomania--successful treatment with fluvoxamine and cognitive-behavioral psychotherapy. Psychiatr Danub. 2005;17:97-100 pubmed
    ..We have presented the case of a 32-year old woman with a history of excessive pathological buying treated successfully with combined therapy (fluvoxamine and cognitive-behavioral psychotherapy).
  16. Karunatilake H, Buckley N. Serotonin syndrome induced by fluvoxamine and oxycodone. Ann Pharmacother. 2006;40:155-7 pubmed
    To report a case of severe serotonergic symptoms following the addition of oxycodone to fluvoxamine.
  17. Tagashira H, Bhuiyan S, Shioda N, Hasegawa H, Kanai H, Fukunaga K. Sigma1-receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice. Am J Physiol Heart Circ Physiol. 2010;299:H1535-45 pubmed publisher
    ..Here, we investigated the role of ?(1)-receptor (?(1)R) stimulation with fluvoxamine on myocardial hypertrophy and cardiac functional recovery...
  18. Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol. 2010;25:193-200 pubmed publisher
    ..of the involvement of sigma-1 receptor agonism in the mechanism of action of some antidepressants, notably fluvoxamine. Sigma-1 receptors are abundant in areas affected by depression/stress-induced cerebral atrophy and their ..
  19. Okuda A, Suzuki T, Kishi T, Yamanouchi Y, Umeda K, Haitoh H, et al. Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder. Psychiatry Clin Neurosci. 2010;64:268-73 pubmed publisher
    ..The aim of this study was to analyze the relation between treatment response and the duration of untreated illness (DUI) in 133 outpatients with the first major depressive disorder (MDD) episode...
  20. Otsubo T, Akimoto Y, Yamada H, Koda R, Aoyama H, Tanaka K, et al. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression. Pharmacopsychiatry. 2005;38:30-5 pubmed
    The aim of this study was to compare the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
  21. Rota E, Broda R, Cangemi L, Migliaretti G, Paccotti P, Rosso C, et al. Neuroendocrine (HPA axis) and clinical correlates during fluvoxamine and amitriptyline treatment. Psychiatry Res. 2005;133:281-4 pubmed
    ..effect of amitriptyline on hypothalamic-pituitary-adrenocortical (HPA) axis activity was compared with that of fluvoxamine in 38 patients suffering from DMS-IV major depressive disorder...
  22. Ginsburg B, Lamb R. Reinforcement magnitude modulation of rate-dependent effects of fluvoxamine and desipramine in the rat. Behav Pharmacol. 2008;19:829-35 pubmed publisher
    Reinforcement magnitude modulates the effects of the antidepressants fluvoxamine and desipramine in the pigeon. Increasing reinforcement magnitude diminishes the rate-dependent effects of these drugs...
  23. Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE. 2008;3:e2558 pubmed publisher
    ..However, their pharmacology is quite heterogeneous. The SSRI fluvoxamine, with sigma-1 receptor agonism, is shown to potentiate nerve-growth factor (NGF)-induced neurite outgrowth in ..
  24. Morishita S, Arita S. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age. Hum Psychopharmacol. 2004;19:405-8 pubmed
    ..It seems that an investigation of the characteristics of patients being treated with SSRIs and SNRIs would be useful in determining which patients would be most likely to benefit from these antidepressant medications...
  25. de Jong T, Snaphaan L, Pattij T, Veening J, Waldinger M, Cools A, et al. Effects of chronic treatment with fluvoxamine and paroxetine during adolescence on serotonin-related behavior in adult male rats. Eur Neuropsychopharmacol. 2006;16:39-48 pubmed
    ..Male Wistar rats were treated with paroxetine (15 mg/kg p.o.) or fluvoxamine (30 mg/kg p.o.) throughout adolescence...
  26. Westenberg H, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract. 2006;60:482-91 pubmed
    ..Although SSRIs (and venlafaxine) have similar adverse effects, certain differences are emerging. Fluvoxamine may have fewer effects on sexual dysfunction and sleep pattern...
  27. Yoshida K, Higuchi H, Kamata M, Takahashi H, Inoue K, Suzuki T, et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol. 2007;21:650-6 pubmed
    ..is associated with the antidepressant effect of milnacipran, a serotonin norepinephrine reuptake inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor...
  28. Koran L, Bromberg D, Hornfeldt C, Shepski J, Wang S, Hollander E. Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder. Compr Psychiatry. 2010;51:373-9 pubmed publisher
    We hypothesized that subjects with obsessive-compulsive disorder (OCD) who received extended-release fluvoxamine (fluvoxamine ER) in a 12-week placebo-controlled trial would exhibit improvements in psychosocial domains of health-related ..
  29. Nonogaki K, Nozue K, Takahashi Y, Yamashita N, Hiraoka S, Kumano H, et al. Fluvoxamine, a selective serotonin reuptake inhibitor, and 5-HT2C receptor inactivation induce appetite-suppressing effects in mice via 5-HT1B receptors. Int J Neuropsychopharmacol. 2007;10:675-81 pubmed
    ..Here, we report that fluvoxamine (3-30 mg/kg), a selective serotonin reuptake inhibitor (SSRI), in the presence of SB 242084 (1-2 mg/kg), a ..
  30. Venerosi A, Ricceri L, Rungi A, Sanghez V, Calamandrei G. Gestational exposure to the organophosphate chlorpyrifos alters social-emotional behaviour and impairs responsiveness to the serotonin transporter inhibitor fluvoxamine in mice. Psychopharmacology (Berl). 2010;208:99-107 pubmed publisher
    ..Studies from animal models indicate that CPF exposure during development at low doses can target different neurotransmitter systems in the absence of overt cholinergic effects...
  31. Stirnimann G, Petitprez S, Abriel H, Schwick N. Brugada syndrome ECG provoked by the selective serotonin reuptake inhibitor fluvoxamine. Europace. 2010;12:282-3 pubmed publisher
    ..to a non-expression of the mutant allele, was prescribed the selective serotonin reuptake inhibitor (SSRI) fluvoxamine (Floxyfral), 100 mg per day. His normal baseline ECG changed to a characteristic Brugada-Type-1-ECG pattern...
  32. Kato M, Ikenaga Y, Wakeno M, Okugawa G, Nobuhara K, Fukuda T, et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol. 2005;20:151-6 pubmed
    ..Clinical responses to paroxetine and fluvoxamine were evaluated by total and cluster depressive symptoms for 81 Japanese patients who were diagnosed with major ..
  33. Kishi T, Kitajima T, Ikeda M, Yamanouchi Y, Kinoshita Y, Kawashima K, et al. CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients. Neuromolecular Med. 2009;11:53-7 pubmed publisher
    ..Therefore, we examined the association between CLOCK and the efficacy of fluvoxamine treatment in 121 patients with Japanese major depressive disorder (MDD)...
  34. Shinozaki T, Kimura M, Hosoyamada M, Shibasaki T. Fluvoxamine inhibits weight gain and food intake in food restricted hyperphagic Wistar rats. Biol Pharm Bull. 2008;31:2250-4 pubmed
    The effects of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), were studied in normophagic and food-restriction-induced hyperphagic middle-aged Wistar rats...
  35. Moresco R, Pietra L, Henin M, Panzacchi A, Locatelli M, Bonaldi L, et al. Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naïve patients. Neuropsychopharmacology. 2007;32:197-205 pubmed
    ..the brain of a group of OCD naïve patients before and after the repeated administration of the inhibitor SSRI fluvoxamine. Eight patients with a Diagnostic and Statistical Manual of Mental Disorders IVth edition diagnosis of OCD ..
  36. Orlando R, Padrini R, Perazzi M, De Martin S, Piccoli P, Palatini P. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Clin Pharmacol Ther. 2006;79:489-99 pubmed
    In vivo inhibition of cytochrome P450 (CYP) 1A2 by fluvoxamine causes a reduction in the clearance of the high-extraction drug lidocaine, which decreases in proportion to the degree of liver dysfunction...
  37. Yoshimura R, Kaneko S, Shinkai K, Nakamura J. Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels. Psychiatry Clin Neurosci. 2006;60:389-93 pubmed
    ..treatment of obsessive-compulsive disorder (OCD) in three patients with the addition of risperidone to ongoing fluvoxamine treatment...
  38. Ständer S, Böckenholt B, Schürmeyer Horst F, Weishaupt C, Heuft G, Luger T, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol. 2009;89:45-51 pubmed publisher
    ..Paroxetine and fluvoxamine were tested in a total of 72 pruritic patients (27 men, 45 women, age range 28-88 years, mean age 59.2 years)...
  39. Darwish I, Amer S, Abdine H, Al Rayes L. Spectrofluorimetric determination of fluvoxamine in dosage forms and plasma via derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole. J Fluoresc. 2009;19:463-71 pubmed publisher
    ..simple spectrofluorimetric method has been developed and validated for the determination of the antidepressant fluvoxamine (FXM) in its dosage forms and plasma...
  40. Egashira N, Harada S, Okuno R, Matsushita M, Nishimura R, Mishima K, et al. Involvement of the sigma1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: comparison with paroxetine. Eur J Pharmacol. 2007;563:149-54 pubmed
    ..of the sigma1 receptor in the inhibitory effect of the selective serotonin reuptake inhibitor (SSRI) fluvoxamine, compared with that of paroxetine, on marble-burying behavior, which is an animal model of obsessive-compulsive ..
  41. Saito S, Takahashi N, Ishihara R, Ikeda M, Suzuki T, Kitajima T, et al. Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients. Neuropsychobiology. 2006;54:226-30 pubmed
    ..The purpose of this study was to investigate whether the VAMP2 gene is associated with clinical responses to a specific antidepressant, fluvoxamine.
  42. Pedersen R, Damkier P, Brosen K. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol. 2006;62:682-9 pubmed
    To determine the effect of CYP2C8 genotype and of fluvoxamine on the pharmacokinetics of rosiglitazone.
  43. Culm Merdek K, von Moltke L, Harmatz J, Greenblatt D. Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. Br J Clin Pharmacol. 2005;60:486-93 pubmed
    Coadministration of fluvoxamine impairs the clearance of caffeine and prolongs its elimination half-life, which is attributable to inhibition of CYP1A2 by fluvoxamine. The clinical importance of this interaction is not established.
  44. von Richter O, Lahu G, Huennemeyer A, Herzog R, Zech K, Hermann R. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. Clin Pharmacokinet. 2007;46:613-22 pubmed
    To investigate the effects of steady-state dosing of fluvoxamine, an inhibitor of cytochrome P450 (CYP) 1A2 and CYP2C19, on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor and its ..
  45. Naito S, Sato K, Yoshida K, Higuchi H, Takahashi H, Kamata M, et al. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients. Psychiatry Clin Neurosci. 2007;61:421-7 pubmed
    Gender differences in the treatment response to fluvoxamine (selective serotonin re-uptake inhibitor) and milnacipran (serotonin/norepinephrine re-uptake inhibitor) were investigated in Japanese major depressive patients...
  46. Chertkow Y, Weinreb O, Youdim M, Silver H. Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1356-62 pubmed
    ..Gene expression profile of PMC from antipsychotic-treated patients was examined before addition of the SSRI fluvoxamine, and 3 and 6 weeks after...
  47. Chung S, You I, Cho G, Chung G, Shin Y, Kim D, et al. Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine. Yonsei Med J. 2009;50:441-4 pubmed publisher
    ..We present a case of a 36-year-old pathological gambler who was treated with fluvoxamine, a selective serotonin reuptake inhibitor, and who was assessed by functional MRI before and after drug ..
  48. Ago Y, Harasawa T, Itoh S, Nakamura S, Baba A, Matsuda T. Antidepressant-like effect of coadministration of sulpiride and fluvoxamine in mice. Eur J Pharmacol. 2005;520:86-90 pubmed
    We have recently reported that coadministration of sulpiride, an antipsychotic drug, and fluvoxamine, a selective serotonin (5-HT) reuptake inhibitor, selectively increases in vivo dopamine release in the prefrontal cortex...
  49. Dannon P, Lowengrub K, Gonopolski Y, Musin E, Kotler M. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol. 2005;28:6-10 pubmed
    ..The aim of the study is to compare the effectiveness of topiramate versus fluvoxamine in the treatment of PG...
  50. Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry. 2007;62:878-83 pubmed
    ..Among the several SSRIs, fluvoxamine has the highest affinity for sigma-1 receptors (Ki = 36 nM), whereas paroxetine shows low affinity (Ki = 1893 ..
  51. Horii A, Uno A, Kitahara T, Mitani K, Masumura C, Kizawa K, et al. Effects of fluvoxamine on anxiety, depression, and subjective handicaps of chronic dizziness patients with or without neuro-otologic diseases. J Vestib Res. 2007;17:1-8 pubmed
    A prospective, open-label clinical trial was conducted for two aims: first, to evaluate the role of fluvoxamine, one of selective serotonin reuptake inhibitors, in the treatment of dizziness for the first time and to investigate its ..
  52. Benmansour S, Piotrowski J, Altamirano A, Frazer A. Impact of ovarian hormones on the modulation of the serotonin transporter by fluvoxamine. Neuropsychopharmacology. 2009;34:555-64 pubmed publisher
    ..Local application of the SSRI, fluvoxamine, directly into the CA3 area of hippocampus increased significantly 5-HT clearance time parameters in male rats ..
  53. Honda M, Uchida K, Tanabe M, Ono H. Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A/2C receptors. Neuropharmacology. 2006;51:866-72 pubmed
    ..We examined the effects of fluvoxamine, a selective serotonin reuptake inhibitor, on mechanical allodynia and its mechanism of action in the mouse ..
  54. Okumura T, Kishi T, Okochi T, Ikeda M, Kitajima T, Yamanouchi Y, et al. Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population. Neuropsychobiology. 2010;61:57-63 pubmed publisher
    ..Therefore, we studied the association of nNOS gene (NOS1) and mood disorders and the efficacy of fluvoxamine treatment in Japanese MDD patients.
  55. van Oppen P, van Balkom A, de Haan E, Van Dyck R. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. J Clin Psychiatry. 2005;66:1415-22 pubmed
    ..effectiveness of cognitive therapy (CT) and to compare long-term effectiveness of CT alone, exposure in vivo with response prevention (ERP) alone, and CBT (either CT or ERP) in combination with fluvoxamine in the treatment of OCD.
  56. Benedetti F, Dallaspezia S, Colombo C, Lorenzi C, Pirovano A, Smeraldi E. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Eur Psychiatry. 2010;25:476-8 pubmed publisher
    ..Recent clinical studies found a significant effect of rs4680 on antidepressant response to fluoxetine and paroxetine, but several other studies were negative. No study considered drug plasma levels as possible nuisance covariate...
  57. Milano W, Siano C, Putrella C, Capasso A. Treatment of bulimia nervosa with fluvoxamine: a randomized controlled trial. Adv Ther. 2005;22:278-83 pubmed
    ..We conducted a randomized controlled trial to verify the efficacy of the SSRI fluvoxamine in patients with a diagnosis of BN...
  58. Hashimoto K. Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia?. CNS Neurol Disord Drug Targets. 2009;8:470-4 pubmed
    ..Among all antidepressants, fluvoxamine was the most potent sigma-1 receptor agonist...
  59. Uno T, Shimizu M, Yasui Furukori N, Sugawara K, Tateishi T. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol. 2006;61:309-14 pubmed
    ..Our objective was to evaluate the possible effect of an inhibitor of CYP2C19, fluvoxamine, and compare the inhibitory effect of fluvoxamine on the metabolism of rabeprazole between CYP2C19 genotypes.
  60. Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65:1365-71 pubmed
    ..The aim of the present study was to assess changes in weight in obsessive-compulsive disorder (OCD) patients treated for 2.5 years with clomipramine or selective serotonin reuptake inhibitors...
  61. Isohanni M, Neuvonen P, Olkkola K. Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine. Basic Clin Pharmacol Toxicol. 2006;99:168-72 pubmed
    ..We studied the effect of co-administration of fluvoxamine (CYP1A2 inhibitor) and erythromycin (CYP3A4 inhibitor) on the pharmacokinetics of lidocaine in a double-blind, ..